Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Feb 15;101(4):819–826. doi: 10.1172/JCI1578

Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.

T Takano 1, C B Clish 1, K Gronert 1, N Petasis 1, C N Serhan 1
PMCID: PMC508630  PMID: 9466977

Abstract

Neutrophil (PMN) activation is critical in inflammation and reperfusion injury, suggesting that PMN-directed therapies may be of clinical use. Here, leukotriene B4 (LTB4)-induced PMN influx in ear skin was equivalent between 5-lipoxygenase knockout and wild-type mice. To explore actions of lipoxin (LX) in PMN-mediated tissue injury, we prepared several novel LX stable analogues, including analogues of LXA4 and aspirin-triggered 15-epi-LXA4 as well as LXB4, and examined their impact in PMN infiltration and vascular permeability. Each applied topically to mouse ears inhibited dramatically PMN-mediated increases in vascular permeability (IC50 range of 13-26 nmol) with a rank order of 15(R/S)-methyl-LXA4 > 16-para-fluoro-phenoxy-LXA4 approximately 5(S)-methyl-LXB4 >/= 16-phenoxy-LXA4 > 5(R)-methyl-LXB4. These LX mimetics were as potent as an LTB4 receptor antagonist, yet results from microphysiometry with mouse leukocytes indicated that they do not act as LTB4 receptor level antagonists. In addition, within 24 h of delivery, > 90% were cleared from ear biopsies. Neither IL-8, FMLP, C5a, LTD4, nor platelet-activating factor act topically to promote PMN influx. When applied with LTB4, PGE2 enhanced sharply both infiltration and vascular permeability, which were inhibited by a fluorinated stable analogue of aspirin-triggered LX. These results indicate that mimetics of LXs and aspirin-triggered 15-epi-LXA4 are topically active in this model and are potent inhibitors of both PMN infiltration and PMN-mediated vascular injury.

Full Text

The Full Text of this article is available as a PDF (268.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borgeat P., Naccache P. H. Biosynthesis and biological activity of leukotriene B4. Clin Biochem. 1990 Oct;23(5):459–468. doi: 10.1016/0009-9120(90)90272-v. [DOI] [PubMed] [Google Scholar]
  2. Colgan S. P., Serhan C. N., Parkos C. A., Delp-Archer C., Madara J. L. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest. 1993 Jul;92(1):75–82. doi: 10.1172/JCI116601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Falcone R. C., Aharony D. Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes by sulfhydryl modifying reagents. J Pharmacol Exp Ther. 1990 Nov;255(2):565–571. [PubMed] [Google Scholar]
  4. Fiore S., Ryeom S. W., Weller P. F., Serhan C. N. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem. 1992 Aug 15;267(23):16168–16176. [PubMed] [Google Scholar]
  5. Hedqvist P., Lindbom L., Palmertz U., Raud J. Microvascular mechanisms in inflammation. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:91–99. [PubMed] [Google Scholar]
  6. Lee T. H., Horton C. E., Kyan-Aung U., Haskard D., Crea A. E., Spur B. W. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond) 1989 Aug;77(2):195–203. doi: 10.1042/cs0770195. [DOI] [PubMed] [Google Scholar]
  7. McConnell H. M., Owicki J. C., Parce J. W., Miller D. L., Baxter G. T., Wada H. G., Pitchford S. The cytosensor microphysiometer: biological applications of silicon technology. Science. 1992 Sep 25;257(5078):1906–1912. doi: 10.1126/science.1329199. [DOI] [PubMed] [Google Scholar]
  8. Papayianni A., Serhan C. N., Brady H. R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol. 1996 Mar 15;156(6):2264–2272. [PubMed] [Google Scholar]
  9. Serhan C. N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins. 1997 Feb;53(2):107–137. doi: 10.1016/s0090-6980(97)00001-4. [DOI] [PubMed] [Google Scholar]
  10. Serhan C. N., Maddox J. F., Petasis N. A., Akritopoulou-Zanze I., Papayianni A., Brady H. R., Colgan S. P., Madara J. L. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 1995 Nov 7;34(44):14609–14615. doi: 10.1021/bi00044a041. [DOI] [PubMed] [Google Scholar]
  11. Takano T., Fiore S., Maddox J. F., Brady H. R., Petasis N. A., Serhan C. N. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997 May 5;185(9):1693–1704. doi: 10.1084/jem.185.9.1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tamaoki J., Tagaya E., Yamawaki I., Konno K. Lipoxin A4 inhibits cholinergic neurotransmission through nitric oxide generation in the rabbit trachea. Eur J Pharmacol. 1995 Dec 20;287(3):233–238. doi: 10.1016/0014-2999(95)00490-4. [DOI] [PubMed] [Google Scholar]
  13. Varani J., Ward P. A. Mechanisms of neutrophil-dependent and neutrophil-independent endothelial cell injury. Biol Signals. 1994 Jan-Feb;3(1):1–14. doi: 10.1159/000109521. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES